RxDoctor Payments DataLook up a doctor →

Keith Watts

Psychiatric/Mental Health · Madison, ALNPI 1710432190

Payments from drug & device makers

$13,194in general payments, 2019–2025

Across 673 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alkermes, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Otsuka America Pharmaceutical, Inc.$808
  • Johnson & Johnson$764
  • Corium, LLC$762
  • plus $6K from 29 others

What the payments were for

  • Food & beverage$13,133100%
  • Education$610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,194 in reported general payments places this provider in the 95th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Medicare billing

Part B allowed, 2024
$40,014
Medicare patients
58
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AplenzinBupropion Hbr23$97,307
VraylarCariprazine Hcl35$50,957
CaplytaLumateperone Tosylate18$37,841
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl33$8,796
Chlorpromazine Hcl39$8,267
TrintellixVortioxetine Hydrobromide12$5,599
Lurasidone Hcl33$4,719
Lamotrigine ErLamotrigine16$3,865
Duloxetine Hcl72$3,245
Oxcarbazepine56$3,211
Quetiapine Fumarate179$2,993
Bupropion XlBupropion Hcl136$2,602
Lisdexamfetamine Dimesylate11$2,557
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine74$2,494
Desvenlafaxine Succinate ErDesvenlafaxine Succinate52$2,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch Health US, LLCAplenzin$704$97,30723 claims
AbbVieVraylar$1,880$50,95735 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,314$37,84118 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$647$5,59912 claims
Almatica Pharma LLCSertraline Hcl$409$30738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Madison

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →